Optune Lua Revenue -- $10.4 million for the year, including $5.8 million from non-small cell lung cancer; recognized $3.5 ...
NovoCure Limited (NASDAQ:NVCR) Q4 2025 Earnings Call Transcript February 26, 2026 NovoCure Limited beats earnings ...
Precision BioSciences, Inc. , a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results